Zheng Haoqi, Yu Xiuhua, Chen Yuquan, Lin Wenying, Liu Li
Department of Pediatrics, The First Hospital of Jilin University, Changchun, China.
Institute of Medical Information/Library, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Pediatr. 2022 May 10;10:827508. doi: 10.3389/fped.2022.827508. eCollection 2022.
Post-infectious bronchiolitis obliterans (PIBO) is a rare and irreversible chronic obstructive pulmonary disease with no specific treatment, especially for patients with PIBO in remission. In this study, we evaluated the effects of continuous inhaled corticosteroids (ICSs) and intermittent ICSs on lung function in the remission of PIBO.
This was a retrospective study, and all the subjects we included were divided into continuous ICS group and intermittent ICS group according to treatment regimens. Patients in continuous ICS group received continuous ICSs (2 times a day), and patients in intermittent ICS group received intermittent ICSs (inhaled corticosteroids after acute respiratory tract infection or wheezing). Different lung function tests were performed at different ages. Tidal breathing lung function tests were performed in patients with PIBO aged ≤ 5 years, and the lung ventilation function test and the bronchial dilation test were performed in patients with PIBO aged more than 5 years. Lung function was assessed at the beginning of follow-up and at the end of follow-up (1 year of ICSs).
After 1 year of ICSs, patients aged more than 5 years, forced vital capacity (FVC), and forced expiratory volume in 1 s (FEV) were significantly higher than at the beginning of follow-up. After 1 year of ICSs, the difference in V/Kg, TPTEF/TE, and VPEF/VE between the end and the beginning of follow-up in continuous ICS group shows an upward trend. But those showed a downward trend in intermittent ICS group. FVC, FEV, and maximal mid-expiratory flow velocity 25-75% (MMEF) of continuous ICS group were significantly higher than at the beginning of follow-up. The difference in FEV and MMEF between the end of follow-up and the beginning of follow-up in continuous ICS group was significantly higher than that in intermittent ICS group. A total of 52.94% of patients with PIBO aged more than 5 years were positive for bronchial dilation tests.
Inhaled corticosteroids can effectively improve lung function and relieve airway obstruction in patients aged more than 5 years in PIBO remission, especially continuous ICSs. Patients with PIBO may have reversible airflow limitations.
感染后闭塞性细支气管炎(PIBO)是一种罕见的、不可逆的慢性阻塞性肺疾病,尚无特效治疗方法,尤其是对于处于缓解期的PIBO患者。在本研究中,我们评估了持续吸入糖皮质激素(ICS)和间歇吸入ICS对PIBO缓解期肺功能的影响。
这是一项回顾性研究,我们纳入的所有受试者根据治疗方案分为持续ICS组和间歇ICS组。持续ICS组患者接受持续ICS治疗(每日2次),间歇ICS组患者接受间歇ICS治疗(急性呼吸道感染或喘息后吸入糖皮质激素)。在不同年龄段进行不同的肺功能测试。对年龄≤5岁的PIBO患者进行潮气呼吸肺功能测试,对年龄>5岁的PIBO患者进行肺通气功能测试和支气管舒张试验。在随访开始时和随访结束时(ICS治疗1年)评估肺功能。
ICS治疗1年后,年龄>5岁患者的用力肺活量(FVC)和第1秒用力呼气容积(FEV)显著高于随访开始时。ICS治疗1年后,持续ICS组随访结束时与开始时相比,V/Kg、TPTEF/TE和VPEF/VE的差异呈上升趋势。但间歇ICS组呈下降趋势。持续ICS组的FVC、FEV和25%-75%最大呼气中期流速(MMEF)显著高于随访开始时。持续ICS组随访结束时与开始时相比,FEV和MMEF的差异显著高于间歇ICS组。年龄>5岁的PIBO患者中共有52.94%支气管舒张试验呈阳性。
吸入糖皮质激素可有效改善PIBO缓解期年龄>5岁患者的肺功能,缓解气道阻塞,尤其是持续ICS治疗。PIBO患者可能存在可逆性气流受限。